| __timestamp | Alnylam Pharmaceuticals, Inc. | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 1244910 |
| Thursday, January 1, 2015 | 60610000 | 5029636 |
| Friday, January 1, 2016 | 89354000 | 4846776 |
| Sunday, January 1, 2017 | 199365000 | 5329003 |
| Monday, January 1, 2018 | 382359000 | 7121000 |
| Tuesday, January 1, 2019 | 479005000 | 9128000 |
| Wednesday, January 1, 2020 | 588420000 | 10731000 |
| Friday, January 1, 2021 | 620639000 | 10701000 |
| Saturday, January 1, 2022 | 770658000 | 16121000 |
| Sunday, January 1, 2023 | 795646000 | 37021000 |
| Monday, January 1, 2024 | 975526000 |
In pursuit of knowledge
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Alnylam Pharmaceuticals, Inc. and Viking Therapeutics, Inc. have shown contrasting approaches over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, peaking at nearly $800 million in 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Viking Therapeutics maintained a more conservative growth, with SG&A costs increasing by approximately 2,900% but still only reaching about $37 million in 2023. This stark difference highlights Viking's lean operational strategy compared to Alnylam's expansive approach. As investors and industry analysts evaluate these companies, understanding their cost management strategies provides valuable insights into their long-term sustainability and market positioning.
Operational Costs Compared: SG&A Analysis of Novartis AG and Alnylam Pharmaceuticals, Inc.
Novartis AG and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of argenx SE and Viking Therapeutics, Inc.
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Viking Therapeutics, Inc.
Comparing SG&A Expenses: Amneal Pharmaceuticals, Inc. vs Viking Therapeutics, Inc. Trends and Insights
Viking Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated